Team leadership of Ethicon Spine specialty, SURGIFLO, EVARREST & Biosurgery Platform strategy• Excelled in recruiting, coaching, and developing marketing team• Led Biosurgery focused Area Sales team calls driving increasing collaboration & conversions• Team developed Business Case for US launch of EVARREST driving 30% YOY growth

• Developed & executed strategy to deliver SURGIFLO sales & share growth, +4 share pts becoming market share leader• Launched innovative surgeon Non personal promotion exceeded benchmark CTR • Led National Training meeting roll out of SURGIFLO enhanced messaging• Built Ethicon leadership in Spine with significant advancement in Key Opinion leader relationship, +6• Led reintroduction of SURGIFLO back to market after 4 month stop shipment

• Successfully lead the launch of EVICEL Lap ASA. Launched 3months early exceeded 1st year sales• Launched professional campaign with differentiated messaging and tools (print & digital)• Experience in recruiting, coaching, managing and developing marketing manager • Commercial input and evaluation into transformational business development deal

• Flawless execution of new EVICEL professional campaign resulted in return to double digit growth • Partnered to develop head to head real-world evidence for EVICEL driving increased conversions• Collaborated with key opinion leaders to drive new product development insights and feedback• Led globalization launch of EVICEL in Asia and Latin America. Exceeded 1st yr sales projections

Global launch lead for SIMPONI in Ulcerative Colitis, exceeded year 1 forecast• Delivered exceptional results through development of SIMPONI UC positioning & co-positioning• Built impactful SIMPONI UC professional creative campaign and message platform• Empowered alliance management partnering with global partner, Merck. Built aligned platform• Built commercial strategy & case to fund phase 2 SIMPONI companion diagnostic clinical trial

Lead global patient based modeling efforts for SIMPONI along with other immunology products in development, CNTO 136, and immunology business development opportunities• Strategic planning leadership: Drove analysis and triangulation of multiple data sources to inform the 2008 golimumab rheumatology and gastroenterology strategic plan patient based models. Key data inputs and recommendations were made on competitive share and interpretation and application of current market research• Rheumatology co-positioning: Drove analysis identifying key patient source of volume in rheumatoid arthritis for optimal co-positioning recommendation for golimumab and Remicade supported with line of therapy analysis• Cross functional communication: Led bi-weekly meetings with R&D finance, operations, and portfolio analysis ensuring team alignment on current strategic commercial imperatives• Market knowledge: Sought out and engaged people within J&J leading to a rheumatology sales rep ride along to further my knowledge of the current marketplace while continuing to complete marketing excellence training• Recognition: Awarded two Platinum Encore award for results achieved in executing scenarios in RA disease model and for strategic thinking on a licensing deal, Project Symbol• New product forecast breadth: Led global forecasting efforts for two new anti-infective products launches, doripenem and ceftobiprole. Provided forecast support for commercial functional reviews and launch review